Literature DB >> 1349529

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

E Spina1, M Ancione, A E Di Rosa, M Meduri, A P Caputi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349529     DOI： 10.1007/bf00266363

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.

Authors:  C von Bahr; G Movin; C Nordin; A Lidén; M Hammarlund-Udenaes; A Hedberg; H Ring; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1991-03       Impact factor: 6.875

2.  Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.

Authors:  J W Meyer; B Woggon; P Baumann; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.

Authors:  M L Dahl-Puustinen; A Lidén; C Alm; C Nordin; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

5.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

Review 6.  The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.

Authors:  C D Marsden; P Jenner
Journal:  Psychol Med       Date:  1980-02       Impact factor: 7.723

7.  Debrisoquine oxidation phenotype during neuroleptic monotherapy.

Authors:  E Spina; C Martines; A P Caputi; J Cobaleda; B Piñas; J A Carrillo; J Benitez
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

9.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

Authors:  E K Syvälahti; R Lindberg; J Kallio; M De Vocht
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962
View more
  11 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.

Authors:  Julia Kirchheiner; Cristina Rodriguez-Antona
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Formation of pyridinium species of haloperidol in human liver and brain.

Authors:  D W Eyles; J J McGrath; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

Review 5.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 6.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

7.  Pharmacokinetics of chlorpromazine and key metabolites.

Authors:  P K Yeung; J W Hubbard; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.

Authors:  P Glue; R P Clement
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 9.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 10.  Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

Authors:  Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.